Parkinson’s disease Archive — Page 2 of 3
-
November 26, 2014
New tools to probe manganese biology
Vanderbilt researchers have developed tools to probe the role of the essential metal manganese in neurons, and which offer a started point for developing therapeutic agents for manganese-related neurological disorders. -
August 14, 2014
Team takes 4-D look at brain receptor’s role
Reporting last week in the journal Cell, researchers from Oregon Health and Science University, Harvard Medical School and Vanderbilt University describe the first “four-dimensional” picture of a brain receptor that plays a key role in learning and memory. -
April 3, 2014
DBS for Parkinson’s trial moves to next level
A long-term Vanderbilt University Medical Center study of deep brain stimulation (DBS) in early-stage Parkinson’s disease has received approval from the Food and Drug Administration (FDA) to continue in a pivotal, phase III, large-scale safety and efficacy trial. -
March 13, 2014
‘Missing link’ may spur new brain disorder drugs
Researchers at the Scripps Research Institute in San Diego and Vanderbilt University have discovered a “missing link” in the structure of a transmembrane receptor that could lead to new treatments for autism, schizophrenia, Parkinson’s disease and Alzheimer’s disease. -
November 11, 2013
Amish aid study of Parkinson genetics
Amish populations are valuable for genetic research because of their isolation, shared ancestry and homogeneous lifestyles. -
May 6, 2013
Newsmakers: Vanderbilt’s teaching, research and patient care efforts are making an impact
These stories from the past year show how Vanderbilt is making an impact, on campus and in the world. -
April 29, 2013
Fava beans’ impact on urine sodium
Eating fava beans increases dopamine in blood and urine, but does not stimulate urinary sodium excretion.